For instance, GT005 (237), an AAV-based therapy encoding Factor I, and HMR59, encoding a soluble form of CD59 (NCT03144999), are being evaluated for their ability to reinstate complement regulation in target tissues in age-related macular degeneration. Here, CD59 is linked to age-related macular degeneration.